Animal Vaccines Market Size, Share & Trends Analysis Report By Product (Attenuated Live Vaccines, Recombinant Vaccines), By Animal Type (Livestock, Companion), By Route Of Administration- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Animal Vaccines market size is expected to hit around USD 27.2 billion by 2030 from valued at USD 11.9 billion in 2021 and growing at a CAGR of 10.3% from 2022 to 2030.

Key Takeaways:

  • By Product, the U.S. Animal Vaccines market was valued at USD 2.9 Billion in 2021 and expected to witness growth at a CAGR of 8.5% from 2022 to 2030.
  • Based on product, attenuated live vaccines emerged as the largest segment in 2021 as a result of the benefits such as improved effectiveness and enhanced long-term prevention. The recombinant vaccine is expected to witness considerable growth during the forecast period. These vaccine formulations can avoid the need for adjuvants, increase the viability of the vaccine, and improve stability
  • The livestock animal type segment dominated the market in 2021. According to Elsevier, Inc., as of February 2020, in Bangladesh, the prevalence of foot and mouth diseases in cattle was 25.30%
  • By route of administration, the intranasal segment is expected to register the fastest growth rate of 10.9% over the projected period owing to its growing popularity
  • North America dominated the market in 2021. Constantly rising awareness regarding livestock health and increasing commercialization of livestock products are factors expected to drive the market in the region during the forecast period
  • In Asia Pacific, the market is projected to witness swift growth during the forecast period owing to the speedy adoption of animal vaccines for quality food products and better animal health
  • Market players are opting for numerous strategies such as partnerships and new product launches. For instance, in October 2021, CZ VACCINES launched a new conjunctival vaccine called B19 CZV Ocular, thus adding a new vaccine to its range of brucellosis vaccines.

Report Scope of the Animal Vaccines Market

Report Coverage

Details

Market Size

USD 27.2 Billion by 2030

Growth Rate

CAGR of 10.3% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Product, animal type, route of administration, and Region,

Companies Mentioned

 Merck & Co., Inc.; Zoetis; Boehringer Ingelheim International GmbH; Virbac; Biogénesis Bagó; Indian Immunologicals Ltd.; Elanco; Ceva; Phibro Animal Health Corporation; Neogen Corporation; Intas Pharmaceuticals Ltd.; Ourofino Saúde Animal

 

The growing incidence of food-borne zoonotic diseases and increasing animal husbandry are boosting the demand for vaccines. Certain transmissible diseases such as bird flu and tuberculosis in invertebrate animals can be transferred directly or indirectly to humans. If consumers eat worms via undercooked fish, they can get contaminated with anisakiasis, a human zoonotic infection caused by some species of nematodes.

The increasing outbreaks of cattle disease and the ever-expanding livestock population are the prime factors for the wide acceptance of the ruminants especially cattle vaccines globally. Moreover, rising pet ownership and increasing awareness regarding the health of companion animals are propelling the market growth. Moreover, the increasing number of R&D investments initiated by the companies is one of the key growth factors. Competition in the market is expected to be high during the forecast period. The market is highly fragmented owing to the presence of several small and large players. This results in high competition among small players to sustain their position in the market.

Moreover, companies are increasingly adopting strategies, such as mergers & acquisitions, geographic expansion, and the launch of new products, to grow in the market. For instance, in December 2020, Elanco acquired exclusive global rights from Kindred Biosciences to its monoclonal antibody for Canine Parvovirus (CPV) called KIND-030. This strengthened the company’s overall vaccine and therapeutics portfolios. Moreover, in September 2020, Ceva enhanced its production capacity at its French facility for bacterial autogenous vaccines. This is expected to support its growth strategy.

Product Insights

The attenuated live vaccines segment dominated the market for animal vaccines and accounted for a revenue share of over 35.0% in 2021. Live attenuation is the oldest vaccination method used in the veterinary field. This method is also under trial for the development of additional applications. Some of these alternatives include the development of protein subunit vaccines for swine, which are given intramuscularly. These products aid in reducing the mortality rate and improve the life span of disease-affected swine.

The recombinant vaccine segment is expected to exhibit lucrative growth over the forecast period. These vaccines help reduce the risk of pathogenicity in animals after vaccination. Recombinant vaccines are also expected to help achieve vaccination against multiple virus strains as recombinants can carry multiple gene inserts. These vaccine formulations can avoid the need for adjuvants, increase the viability of the vaccine, and improve stability. Some of the recombinant vaccines available for veterinary medicine are vaccines against canine distemper, pseudorabies, Newcastle disease, Lyme disease, and avian influenza.

Animal Type Insights

The livestock segment dominated the market with a revenue share of over 70.0% in 2021. This can be attributed to the factors such as rising livestock population, supportive government initiatives, and the outbreak of diseases among cattle and sheep. Vaccinations that are developed for preventing E. coli include Aviguard and Nobilis E. coli inac by Merck & Co., Inc. According to Zoetis, the prevalence rate of E. Coli in various cattle categories (feedlot cattle, cattle on irrigated pasture, cattle at slaughter, and cattle grazing rangeland forages) ranges between 0.2% to 27.8%.

The companion segment is expected to exhibit the fastest growth rate during the forecast period. Canine distemper virus is carried by house pets as well as ferrets and requires strictly preventive vaccination as no post-infection treatment is available. The Morbillivirus affects dogs, foxes, raccoons, and wolves to cause distemper and is transmitted through the air as well as other modes of contact between infected and healthy animals. Immunization of dogs is essential as canine distemper destroys the respiratory, urogenital, and gastrointestinal tract. Dogs suffering from bacterial infections of the gastrointestinal tract and newborn pups are more susceptible to this disease. Vanguard, DHPPi/L Vaccine, DHP, and Megavac 6 and 7 are a few canine distemper vaccines available in the market.

Route of Administration Insights

The subcutaneous segment dominated the market for animal vaccines with a revenue share of over 41.0% in 2021. In most animals, the subcutaneous injection sites are located behind the shoulder blades and neck. Ease of administration of drugs subcutaneously as they can be absorbed slowly into the body is anticipated to boost the market growth. The subcutaneous route of administration is also quicker and less painful for animals. Furthermore, it is easier to train veterinary professionals to administer subcutaneous injections. Intramuscular and subcutaneous are the common routes of administration in animals currently. These factors promote the market growth.

The intranasal segment is expected to exhibit the fastest growth rate of 10.0% during the forecast period owing to its increasing popularity. Mostly, intranasal vaccines are limited to a single dose of vaccine. The growing prevalence of respiratory diseases in animals and rising research activities by market players for the development of better vaccines are expected to fuel the market growth.

Regional Insights

North America dominated the market and accounted for a revenue share of over 26.0% in 2021. The region is expected to remain dominant throughout the forecast period. This large share can be attributed to the high prevalence of livestock and zoonotic diseases leading to large-scale animal deaths. In addition, the large presence of well-established pharmaceutical firms that are consistently striving for wide commercialization of their vaccines and augmenting their geographical reach is expected to boost the market growth. In addition, the rising incidence of canine disorders, which is increasing the adoption of vaccination for the same, and the rising pet population in the U.S. are some of the key factors contributing to the expansion of the regional market.

In Asia Pacific, the market is expected to register the fastest growth rate during the forecast period. The anticipated rise in the livestock population and government initiatives, especially in developing economies, are some of the prime factors expected to boost the market growth in the region. According to the National Dairy Development Board, India’s cattle population was 193.5 million in 2019, as compared to 191.9 million in 2012. Hence, such a large cattle population in the country calls for vaccine demand. The market is driven by high R&D expenditure by many major players, combined with rising attempts for the commercialization of Animal Vaccines and inoculations at tolerably low prices.

Some of the prominent players in the Animal Vaccines Market include:

  • Merck & Co., Inc.
  • Zoetis
  • Boehringer Ingelheim International GmbH
  • Virbac
  • Biogénesis Bagó
  • Indian Immunologicals Ltd.
  • Elanco
  • Ceva
  • Phibro Animal Health Corporation
  • Neogen Corporation
  • Intas Pharmaceuticals Ltd.
  • Ourofino Saúde Animal

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Animal Vaccines market

  • Product
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines
  • Animal Type
    • Livestock
      • Poultry
      • Aqua
      • Ruminants
      • Swine
    • Companion
      • Canine
      • Feline
      • Others
  • Route of Administration
    • Subcutaneous
    • Intramuscular
    • Intranasal

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Animal Vaccines industry analysis from 2022 to 2030 to identify the prevailing Animal Vaccines industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Animal Vaccines industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Animal Vaccines industry trends, key players, market segments, application areas, and market growth strategies.

Chapter 1 Research Methodology & Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Product
                       1.1.2 Animal type
                       1.1.3 Route of Administration
                       1.1.4 Regional Scope
                       1.1.5 Estimates and Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database:
                       1.3.2 Nova one advisor’s Internal Database
                       1.3.3 Secondary sources
                       1.3.4 Primary Research:
                       1.3.5 Details of Primary Research
                           1.3.5.1 Data for primary interviews in North America
                           1.3.5.2 Data for primary interviews in Europe
                           1.3.5.3 Data for primary interviews in Asia Pacific
                           1.3.5.4 Data for primary interviews in Latin America
                           1.3.5.5 Data for primary interviews in Middle East and Africa
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                           1.6.1.1 Approach 1: Commodity Flow Approach
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
                   1.9 Report Objectives
Chapter 2 Executive Summary
                   2.1 Market Outlook
                       2.1.1 Animal Vaccines Market Outlook, 2017 - 2030
                   2.2 Segment Outlook
                   2.3 Animal Vaccines Market Summary, 2021
Chapter 3 Animal Vaccines Market Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market analysis
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Regulatory Framework
                   3.4 Animal Vaccines Market Dynamics
                       3.4.1 Market driver analysis
                           3.4.1.1 Rising livestock population and pet ownership
                           3.4.1.2 Increasing disease outbreaks
                           3.4.1.3 Rising R&D and manufacturing procedural advancements
                           3.4.1.4 Growing demand for animal-derived food products
                           3.4.1.5 regulatory mandates
                       3.4.2 Market restraint analysis
                           3.4.2.1 Government intervention
                           3.4.2.2 Short product exclusivity period
                           3.4.2.3 high storage cost of vaccines
                   3.5 Animal Vaccines Market Analysis Tools: Porters
                       3.5.1 Supplier Power: Low
                       3.5.2 Buyer Power: moderate
                       3.5.3 Threat Of Substitutes: Low
                       3.5.4 Threat Of New Entrants: Moderate
                       3.5.5 Competitive Rivalry: High
                   3.6 PESTEL Analysis
                       3.6.1 Political landscape
                       3.6.2 Economic landscape
                       3.6.3 Social landscape
                       3.6.4 Technology landscape
                       3.6.5 Legal landscape
                   3.7 Major Deals & Strategic Alliances Analysis
                       3.7.1 Mergers & Acquisitions
                       3.7.2 Product Launch
                       3.7.3 Expansion
Chapter 4 Animal Vaccines Market: Competitive Analysis
                   4.1 Market Participation Categorization
                   4.2 Public Companies
                       4.2.1 Company market share/position analysis
                       4.2.2 Competitive Dashboard Analysis
                   4.3 Private Companies
                       4.3.1 List of key emerging companies
Chapter 5 Animal Vaccines Market: COVID Impact Analysis
                   5.1 Impact of Disease Outbreak on The Market
Chapter 6 Animal Vaccines Market: Product Estimates & Trend Analysis
                   6.1 Product Market Share Analysis, 2021 & 2030
                   6.2 Product Dashboard
                   6.3 Global Animal Vaccines Market, By Product, 2017 to 2030
                       6.3.1 Attenuated live vaccines
                           6.3.1.1 Attenuated live vaccines market estimates and forecasts, 2017 - 2030
                       6.3.2 Inactivated vaccines
                           6.3.2.1 Inactivated vaccines market estimates and forecasts, 2017 - 2030
                       6.3.3 Subunit vaccines
                           6.3.3.1 Subunit vaccines market estimates and forecasts, 2017 - 2030
                       6.3.4 DNA vaccines
                           6.3.4.1 DNA vaccines market estimates and forecasts, 2017 - 2030
                       6.3.5 Recombinant vaccines
                           6.3.5.1 Recombinant vaccines market estimates and forecasts, 2017 - 2030
Chapter 7 Animal Vaccines Market: Animal type Estimates & Trend Analysis
                   7.1 Animal Type Market Share Analysis, 2021 & 2030
                   7.2 Animal Type Dashboard
                       7.2.1 Livestock
                           7.2.1.1 Livestock Market by animal type
                           7.2.1.2 Poultry
                               7.2.1.2.1 Poultry market estimates and forecasts, 2017 - 2030
                           7.2.1.3 Aqua
                               7.2.1.3.1 Aqua market estimates and forecasts, 2017 - 2030
                           7.2.1.4 Ruminants
                               7.2.1.4.1 Ruminants market estimates and forecasts, 2017 - 2030
                           7.2.1.5 Swine
                               7.2.1.5.1 Swine market estimates and forecasts, 2017 - 2030
                       7.2.2 Companion
                           7.2.2.1 Companion Market by animal type
                           7.2.2.2 Canine
                               7.2.2.2.1 Canine market estimates and forecasts, 2017 - 2030
                           7.2.2.3 Feline
                               7.2.2.3.1 Feline market estimates and forecasts, 2017 - 2030
                           7.2.2.4 Others
                               7.2.2.4.1 Others market estimates and forecasts, 2017 - 2030
Chapter 8 Animal Vaccines Market: Route of Administration Estimates & Trend Analysis
                   8.1 Route of Administration Market Share Analysis, 2021 & 2030
                   8.2 Route of Administration Dashboard
                   8.3 Global Animal Vaccines Market, By Route of Administration, 2017 to 2030
                       8.3.1 Subcutaneous
                           8.3.1.1 Subcutaneous market estimates and forecasts, 2017 - 2030
                       8.3.2 Intramuscular
                           8.3.2.1 Intramuscular market estimates and forecasts, 2017 - 2030
                       8.3.3 Intranasal
                           8.3.3.1 Intranasal market estimates and forecasts, 2017 - 2030
Chapter 9 Animal Vaccines Market: Regional Estimates & Trend Analysis, by, Product, Animal Type, Route of Administration
                   9.1 Regional Market Snapshot
                   9.2 North America
                       9.2.1 North America Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.2.2 U.S.
                           9.2.2.1 U.S. Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.2.3 Canada
                           9.2.3.1 Canada Animal Vaccines market estimates and forecasts, 2017 - 2030
                   9.3 Europe
                       9.3.1 Europe Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.3.2 U.K.
                           9.3.2.1 U.K. Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.3.3 Germany
                           9.3.3.1 Germany Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.3.4 France
                           9.3.4.1 France Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.3.5 Italy
                           9.3.5.1 Italy Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.3.6 Spain
                           9.3.6.1 Spain Animal Vaccines market estimates and forecasts, 2017 - 2030
                   9.4 Asia Pacific
                       9.4.1 Asia Pacific Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.4.2 Japan
                           9.4.2.1 Japan Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.4.3 China
                           9.4.3.1 China Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.4.4 India
                           9.4.4.1 India Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.4.5 South Korea
                           9.4.5.1 South Korea Animal Vaccines market estimates and forecasts, 2017 - 2030
                   9.5 Latin America
                       9.5.1 Latin America Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.5.2 Brazil
                           9.5.2.1 Brazil Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.5.3 Mexico
                           9.5.3.1 Mexico Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.5.4 Argentina
                           9.5.4.1 Argentina Animal Vaccines market estimates and forecasts, 2017 - 2030
                   9.6 MEA
                       9.6.1 MEA Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.6.2 South Africa
                           9.6.2.1 South Africa Animal Vaccines market estimates and forecasts, 2017 - 2030
                       9.6.3 Saudi Arabia
                           9.6.3.1 Saudi Arabia Animal Vaccines market estimates and forecasts, 2017 - 2030
Chapter 10 Company Profiles
                   10.1 Merck & Co., Inc.
                       10.1.1 Company overview
                       10.1.2 Financial performance
                       10.1.3 Product benchmarking
                       10.1.4 Strategic initiatives
                   10.2 Zoetis
                       10.2.1 Company overview
                       10.2.2 Financial performance
                       10.2.3 Product benchmarking
                       10.2.4 Strategic initiatives
                   10.3 Boehringer Ingelheim International GmbH
                       10.3.1 Company overview
                       10.3.2 Financial performance
                       10.3.3 Product benchmarking
                       10.3.4 Strategic initiatives
                   10.4 Virbac
                       10.4.1 Company overview
                       10.4.2 Financial performance
                       10.4.3 Product benchmarking
                       10.4.4 Strategic initiatives
                   10.5 Biogénesis Bagó
                       10.5.1 Company overview
                       10.5.2 FINANCIAL PERFORMANCE
                       10.5.3 Product benchmarking
                       10.5.4 Strategic initiatives
                   10.6 Indian Immunologicals Ltd.
                       10.6.1 Company overview
                       10.6.2 Product benchmarking
                       10.6.3 Strategic initiatives
                   10.7 Elanco
                       10.7.1 Company overview
                       10.7.2 Financial performance
                       10.7.3 Product benchmarking
                       10.7.4 Strategic initiatives
                   10.8 Ceva
                       10.8.1 Company overview
                       10.8.2 FINANCIAL PERFORMANCE
                       10.8.3 R&D Investment
                       10.8.4 Product benchmarking
                       10.8.5 Strategic initiatives
                   10.9 Phibro Animal Health Corporation
                       10.9.1 Company overview
                       10.9.2 Financial performance
                       10.9.3 Product benchmarking
                       10.9.4 Strategic initiatives
                   10.10 Neogen Corporation
                       10.10.1 Company overview
                       10.10.2 Financial performance
                       10.10.3 Product benchmarking
                       10.10.4 Strategic initiatives
                   10.11 Intas Pharmaceuticals Ltd.
                       10.11.1 Company overview
                       10.11.2 Financial performance
                       10.11.3 Product benchmarking
                       10.11.4 Strategic initiatives
                   10.12 Ourofino Saúde Animal
                       10.12.1 Company overview
                       10.12.2 Financial performance
                       10.12.3 Product benchmarking
                       10.12.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert